Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon epstein-barr virus reactivation in P3HR-1 cells

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 12422-12432

  Coen, Natacha ^a   Duraffour, Sophie ^a   Naesens, Lieve ^a   Krečmerová, Marcela ^b   Oord, Joost Van den ^c   Snoeck, Robert ^a   Andrei, Graciela ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 3 DEAZAADENINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 2' 3' CYCLIC NUCLEOTIDE 3 PHOSPHODIESTERASE; ACYCLIC NUCLEOSIDE; CELL PROTEIN; CIDOFOVIR; CYCLIC AMP; UNCLASSIFIED DRUG; VIRUS PROTEIN; 5-AZACYTOSINE; ANTIVIRUS AGENT; CYCLIC-1-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)CYTOSINE; CYTOSINE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG RESPONSE; DRUG SELECTIVITY; EPSTEIN BARR VIRUS; GAMMAHERPESVIRINAE; HUMAN; HUMAN HERPESVIRUS 8; IN VITRO STUDY; LUNG INFECTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL CULTURE; DRUG EFFECTS; EVALUATION STUDY; HERPESVIRIDAE INFECTIONS; KIDNEY; LYMPHOMA, B-CELL; METABOLISM; TUMOR VIRUS INFECTIONS; VIROLOGY; VIRUS ACTIVATION; WESTERN BLOTTING;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; MURINAE;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC AMP; CYTOSINE; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HUMANS; KIDNEY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; ORGANOPHOSPHONATES; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; TUMOR VIRUS INFECTIONS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84886248309     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02231-13     Document Type: Article

References (48)

1. Cesarman E. 2011. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 305:163-174.
2. Green M, Michaels MG. 2013. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am. J. Transplant. 13(Suppl 3):41-54.
3. Estep RD, Powers MF, Yen BK, Li H, Wong SW. 2007. Construction of an infectious rhesus rhadinovirus bacterial artificial chromosome for the analysis of Kaposi's sarcoma-associated herpesvirus-related disease development. J. Virol. 81:2957-2969.
4. Lin JC. 2000. Strategies for evaluation of antiviral agents against Epstein-Barr virus in culture. Methods Mol. Med. 24:139-150.
5. DeWire SM, McVoy MA, Damania B. 2002. Kinetics of expression of rhesus monkey rhadinovirus (RRV) and identification and characterization of a polycistronic transcript encoding the RRV Orf50/Rta, RRV R8, and R8.1 genes. J. Virol. 76:9819-9831.
6. Miller G, Heston L, Grogan E, Gradoville L, Rigsby M, Sun R, Shedd D, Kushnaryov VM, Grossberg S, Chang Y. 1997. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J. Virol. 71:314-324.
7. Renne R, LagunoffM, Zhong W, Ganem D. 1996. The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J. Virol. 70:8151-8154.
8. Blossom D. 2007. EBV and KSHV, p 1093-1114. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, England.
9. Chang H, Wachtman LM, Pearson CB, Lee JS, Lee HR, Lee SH, Vieira J, Mansfield KG, Jung JU. 2009. Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog. 5(10):e1000606. doi:10.1371/journal.ppat.1000606.
10. Damania B. 2004. Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat. Rev. Microbiol. 2:656-668.
11. Forrest J, Krug L, Speck SH. 2009. Murine gammaherpesvirus 68 infection of mice: a small animal model for characterizing basic aspects of gamma-herpesvirus pathogenesis, p 735-762. In Dammania B, Pipas J (ed), DNA tumor viruses. Springer, New York, NY.
12. Cipkova-Jarcuskova J, Chalupkova A, Hrabovska Z, Wagnerova M, Mistrikova J. 2013. Biological and pathogenetic characterization of different isolates of murine gammaherpesvirus 68 (MHV-68) in the context of study of human oncogenic gammaherpesviruses. Acta Virol. 57:105-112.
13. De Clercq E. 2011. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochem. Pharmacol. 2:99-109.
14. De Clercq E, Holy A. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4:928-940.
15. Cundy KC, Barditch-Crovo P, Petty BG, Ruby A, Redpath M, Jaffe HS, Lietman PS. 1999. Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:271-277.
16. De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hockova D, Holy A. 2005. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 24:331-341.
17. Krecmerova M, Holy A, Piskala A, Masojidkova M, Andrei G, Naesens L, Neyts J, Balzarini J, De CE, Snoeck R. 2007. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl] cytosine (cidofovir) and related compounds. J. Med. Chem. 50:1069-1077.
18. Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. 2004. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res. 62:121-123.
19. Lin JC, De Clercq E, Pagano JS. 1987. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agents Chemother. 31:1431-1433.
20. Lin JC, De Clercq E, Pagano JS. 1991. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35:2440-2443.
21. Meerbach A, Holy A, Wutzler P, De Clercq E, Neyts J. 1998. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir. Chem. Chemother. 9:275-282.
22. Neyts J, De Clercq E. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 41:2754-2756.
23. Murono S, Raab-Traub N, Pagano JS. 2001. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res. 61:7875-7877.
24. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. 1998. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res. 58:384-388.
25. Whitehurst CB, Sanders MK, Law M, Wang FZ, Xiong J, Dittmer DP, Pagano JS. 2013. Maribavir inhibits Epstein-Barr virus (EBV) transcription through the EBV protein kinase. J. Virol. 87:5311-5315.
26. Gulley ML, Tang W. 2010. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23:350-366.
27. Marcelin, AG, Motol J, Guihot A, Caumes E, Viard JP, Dussaix E, Cadranel G, Frances C, Carcelain G, Calvez V, Dupin N. 2007. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHVassociated disease. J. Infect. Dis. 196:1163-1166.
28. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. 2010. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J. Clin. Virol. 49:151-157.
29. Vouloumanou EK, Rafailidis PI, Falagas ME. 2012. Current diagnosis and management of infectious mononucleosis. Curr. Opin. Hematol. 19:14-20.
30. Feng WH, Hong G, Delecluse HJ, Kenney SC. 2004. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78:1893-1902.
31. Gershburg E, Pagano JS. 2005. Epstein-Barr virus infections: prospects for treatment. J. Antimicrob. Chemother. 56:277-281.
32. Kreckmerová M. 2012. Nucleoside and nucleotide analogues for the treatment of herpesvirus infections: current stage and new prospects in the field of acyclic nucleoside phosphonates, p 245-270. In Magel GD, Tyring S (ed), Herpesviridae: a look into this unique family of viruses. http://www.intechopen.com. doi:10.5772/28490.
33. Naesens L, Andrei G, Votruba I, Krecmerova M, Holy A, Neyts J, De Clercq E, Snoeck R. 2008. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Biochem. Pharmacol. 76:997-1005.
34. Coen N, Singh U, Vuyyuru V, Van den Oord JJ, Balzarini J, Duraffour S, Snoeck R, Cheng YC, Chu CK, Andrei G. 2013. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J. Virol. 87:3839-3851.
35. Cihlar T, Chen MS. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
36. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:261-272.
37. Mendel DB, Cihlar T, Moon K, Chen MS. 1997. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob. Agents Chemother. 41:641-646.
38. Stanwick TL, Anderson RW, Nahmias AJ. 1977. Interaction between cyclic nucleotides and herpes simplex viruses: productive infection. Infect. Immun. 18:342-347.
39. Daibata M, Humphreys RE, Takada K, Sairenji T. 1990. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J. Immunol. 144:4788-4793.
40. Daibata M, Humphreys RE, Sairenji T. 1992. Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA. Virology 188:916-920.
41. Fuentes-Panana EM, Peng R, Brewer G, Tan J, Ling PD. 2000. Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway. J. Virol. 74:8166-8175.
42. Bernasconi M, Berger C, Sigrist JA, Bonanomi A, Sobek J, Niggli FK, Nadal D. 2006. Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray. Virol. J. 3:43. doi:10.1186/1743-422X-3-43.
43. Jedlitschky G, Burchell B, Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275:30069-30074.
44. Houslay MD. 1991. 'Crosstalk': a pivotal role for protein kinase C in modulating relationships between signal transduction pathways. Eur. J. Biochem. 195:9-27.
45. Neyts J, De Clercq E. 1998. In vitro and in vivo inhibition of murine gammaherpesvirus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42:170-172.
46. Barnes A, Dyson H, Sunil-Chandra NP, Collins P, Nash AA. 1999.2'-Deoxy-5-ethyl-beta-4'-thiouridine inhibits replication of murine gammaherpesvirus and delays the onset of virus latency. Antivir. Chem. Chemother. 10:321-326.
47. Gantner F, Gotz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br. J. Pharmacol. 123:1031-1038.
48. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. 2003. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278: 17664-17671.